A business in context
JNJ research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-09-08 | Pinto Daniel E | A · Grant / award | Deferred Share Units | 113.1 | 276.31 |
| 2026-09-08 | Woods Eugene A. | A · Grant / award | Deferred Share Units | 135.72 | 276.31 |
| 2026-09-08 | HEWSON MARILLYN A | A · Grant / award | Deferred Share Units | 180.96 | 276.31 |
| 2026-09-02 | Schmid Timothy | S · Sale | Common Stock | 22527.0 | 274.74 |
| 2026-09-02 | Schmid Timothy | S · Sale | Common Stock | 11070.0 | 274.74 |
| 2026-09-02 | Schmid Timothy | M · Exercise / conversion | Common Stock | 11070.0 | 131.94 |
| 2026-09-02 | Schmid Timothy | M · Exercise / conversion | Common Stock | 22527.0 | 151.41 |
| 2026-09-02 | Schmid Timothy | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 11070.0 | 0.0 |
| 2026-09-02 | Schmid Timothy | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 22527.0 | 0.0 |
| 2026-08-17 | Taubert Jennifer L | S · Sale | Common Stock | 15000.0 | 263.36 |
| 2026-08-17 | Taubert Jennifer L | M · Exercise / conversion | Common Stock | 15000.0 | 115.67 |
| 2026-08-17 | Taubert Jennifer L | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 15000.0 | 0.0 |
| 2026-08-13 | Duato Joaquin | S · Sale | Common Stock | 20976.0 | 262.0 |
| 2026-08-13 | Duato Joaquin | M · Exercise / conversion | Common Stock | 123291.0 | 115.67 |
| 2026-08-13 | Duato Joaquin | S · Sale | Common Stock | 102315.0 | 261.0 |
| 2026-08-13 | Duato Joaquin | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 123291.0 | 0.0 |
| 2026-08-06 | Forminard Elizabeth | S · Sale | Common Stock | 6574.0 | 255.93 |
| 2026-08-06 | Forminard Elizabeth | M · Exercise / conversion | Common Stock | 9344.0 | 131.94 |
| 2026-08-06 | Forminard Elizabeth | S · Sale | Common Stock | 9344.0 | 257.76 |
| 2026-08-06 | Forminard Elizabeth | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 9344.0 | 0.0 |
| 2026-08-05 | Duato Joaquin | S · Sale | Common Stock | 41957.0 | 258.06 |
| 2026-08-05 | Duato Joaquin | S · Sale | Common Stock | 6523.0 | 258.74 |
| 2026-07-20 | Broadhurst Vanessa | M · Exercise / conversion | Common Stock | 11129.0 | 129.51 |
| 2026-07-20 | Broadhurst Vanessa | M · Exercise / conversion | Common Stock | 11925.0 | 131.94 |
| 2026-07-20 | Broadhurst Vanessa | S · Sale | Common Stock | 23054.0 | 251.27 |
| 2026-07-20 | Broadhurst Vanessa | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 11129.0 | 0.0 |
| 2026-07-20 | Broadhurst Vanessa | M · Exercise / conversion | Employee Stock Options (Right to Buy) | 11925.0 | 0.0 |
Identity & relationships
SEC issuer · 0000200406JOHNSON & JOHNSON
DePuyJohnson & Johnson Pharmaceutical Research and DevelopmentJanssen BiotechAlzaCilag AGTibotecJohnson & Johnson Consumer CompaniesJohnson & Johnson Health Care SystemsJohnson & Johnson Innovation - JJDC, Inc.Johnson & Johnson Vision CareLifeScanJohnson & Johnson (United Kingdom)Johnson & Johnson (Ireland)Johnson & Johnson (Sweden)Johnson & Johnson (France)
- Legal Entity Identifier
- 549300G0CFPGEF6X2043
- GLEIF legal name
- Johnson & Johnson
- Entity / LEI registration status
- ACTIVE / ISSUED
- Reference data updated
- 2026-07-15T13:22:28Z
Search names and former names
View Wikidata identity and references ↗
- J&J · alias · wikidata
- Johnson and Johnson · alias · wikidata
- DePuy · subsidiary · wikidata
- DePuy, A Johnson & Johnson Company · subsidiary · wikidata
- DePuy Manufacturing · subsidiary · wikidata
- DePuySynthes, A Johnson & Johnson Company · subsidiary · wikidata
- DePuy Synthes Companies of Johnson & Johnson · subsidiary · wikidata
- DePuy Synthes · subsidiary · wikidata
- Johnson & Johnson Pharmaceutical Research and Development · subsidiary · wikidata
- Janssen Research & Development · subsidiary · wikidata
- Johnson & Johnson Pharmaceutical Research & Development · subsidiary · wikidata
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · subsidiary · wikidata
- Janssen Biotech · subsidiary · wikidata
- Centocor · subsidiary · wikidata
- Centocor Biotech · subsidiary · wikidata
- Centocor Ortho Biotech, Inc. · subsidiary · wikidata
- Alza · subsidiary · wikidata
- ALZA Corporation · subsidiary · wikidata
- Cilag AG · subsidiary · wikidata
- Cilag · subsidiary · wikidata
- Tibotec · subsidiary · wikidata
- Johnson & Johnson Consumer Companies · subsidiary · wikidata
- Johnson & Johnson, Group of Consumer Companies · subsidiary · wikidata
- Johnson & Johnson Health Care Systems · subsidiary · wikidata
- Johnson & Johnson Innovation - JJDC, Inc. · subsidiary · wikidata
- Johnson & Johnson Innovation · subsidiary · wikidata
- Johnson & Johnson Vision Care · subsidiary · wikidata
- LifeScan · subsidiary · wikidata
- Johnson & Johnson (United Kingdom) · subsidiary · wikidata
- Johnson & Johnson (Ireland) · subsidiary · wikidata
- Johnson & Johnson (Sweden) · subsidiary · wikidata
- Johnson & Johnson (France) · subsidiary · wikidata
- JOHNSON & JOHNSON ET AL · former SEC name · 1995-10-06 to 1996-01-23
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-29 | $88.82B | $95.41B |
| 2023-12-31 | $85.16B | $94.16B |
| 2023-01-01 | $79.99B | $92.05B |
| 2022-01-02 | $78.74B | $97.85B |
| 2021-01-03 | $82.58B | $107.51B |
| 2019-12-29 | $82.06B | $108.15B |
| 2018-12-30 | $81.58B | $109.46B |
| 2017-12-31 | $76.45B | $105.08B |